Skip to content
10-Q

Quarterly Report

TONGLI PHARMACEUTICALS (USA), INC.

0001144204-13-061797

← back to feed
Filed
Nov 14, 2013 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2013 · Nov 8, 2013 14.73M sh
Operating Cash Flow Q2 2013 · Sep 30, 2013 $1.36M
Operating Cash Flow Q2 2013 · Sep 30, 2012 $321.21K
Stockholders Equity Q2 2013 · Sep 30, 2013 $20.81M
Stockholders Equity Q2 2013 · Mar 31, 2013 $20.47M
Current Liabilities Q2 2013 · Sep 30, 2013 $832.1K
Current Liabilities Q2 2013 · Mar 31, 2013 $1.59M
Current Assets Q2 2013 · Sep 30, 2013 $1.96M
Current Assets Q2 2013 · Mar 31, 2013 $4.07M
Total Assets Q2 2013 · Sep 30, 2013 $21.65M
Total Assets Q2 2013 · Mar 31, 2013 $22.06M
Sga Expense Q2 2013 · Sep 30, 2013 $151.15K
Sga Expense Q2 2013 · Sep 30, 2013 $305.1K
Sga Expense Q2 2013 · Sep 30, 2012 $130.12K
Sga Expense Q2 2013 · Sep 30, 2012 $633.72K
Net Income Q2 2013 · Sep 30, 2013 −$199.67K
Net Income Q2 2013 · Sep 30, 2013 −$118.94K
Net Income Q2 2013 · Sep 30, 2012 $802.39K
Net Income Q2 2013 · Sep 30, 2012 $318.68K
Operating Income Q2 2013 · Sep 30, 2013 −$229.01K
Operating Income Q2 2013 · Sep 30, 2013 −$92.67K
Operating Income Q2 2013 · Sep 30, 2012 $1.15M
Operating Income Q2 2013 · Sep 30, 2012 $534.15K
Gross Profit Q2 2013 · Sep 30, 2013 $0
Gross Profit Q2 2013 · Sep 30, 2013 $372.78K
Gross Profit Q2 2013 · Sep 30, 2012 $1.58M
Gross Profit Q2 2013 · Sep 30, 2012 $1.58M
Cost Of Revenue Q2 2013 · Sep 30, 2013 $0
Cost Of Revenue Q2 2013 · Sep 30, 2013 $380.3K
Cost Of Revenue Q2 2013 · Sep 30, 2012 $1.75M
Cost Of Revenue Q2 2013 · Sep 30, 2012 $1.75M